Since the outbreak of the SARS-CoV-2, we at Elabscience is committed to being your partner and providing you with the tools and support required to enable your COVID-19 research. Researchers around the world are working to deepen their understanding of coronaviruses with a view to quickly determine future treatment options and possible vaccine targets. As a global supplier of life sciences, during this special period, Elabscience® is committed to providing necessary products and services for researchers, developers and manufacturers to help them cope with 2019-nCoV.
Why Should You Choose Elabscience® 2019-nCoV Antibodies?
High antigen purity
Stable quality / High purity / Low endotoxin.
High antibody specificity
Antibodies were obtained by antigen affinity purification.
Multiple antibodies to meet your different research
Spike Antibodies/ Nucleocapsid protein Antibodies / Neutralizing Antibodies/ACE2 Antibodies.
Nucleocapsid protein Antibodies
The coronavirus nucleocapsid protein (N protein) is a structural protein that forms complexes with genomic RNA, interacts with the viral membrane protein during virion assembly and plays a critical role in enhancing the efficiency of virus transcription and assembly.
Spike protein Antibodies
Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The expriment shows that Anti-2019-nCoV S Neutralizing Antibodies can block Human ACE-2 Protein and 2019-nCoV S-trimer Protein interaction.
|Cat. No.||Product Name||Applications|
|E-AB-V1021||Anti-2019-nCoV S-hIgG1 Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1022||Anti-2019-nCoV S-mIgG1 Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1023||Anti-2019-nCoV S-cIgG1 Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1024||Anti-2019-nCoV Spike Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1025||Anti-2019-nCoV Spike Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1026||Anti-2019-nCoV S-IgM Neutralizing Antibody||Neutralization, ELISA|
|E-AB-V1027||Anti-2019-nCoV S-IgA Neutralizing Antibody||Neutralization, ELISA|
IgG / IgM Postive Control
The product is intended for in vitro diagnostic use in the quality control of serum on clinical chemistry and immunoassay systems. The assayed liquid protein controls are for the control of accuracy. For TRFIA assay, antibody can be diluted to 1:50-1:100, the dilution rate should be adjusted based on different testing method.
|Cat. No.||Product Name||Applications|
|E-AB-V1007||SARS-COV-2 Spike Monoclonal Antibody(IgG / IgM Positive Control)||ELISA|
|E-AB-V1017||SARS-COV-2 NP Monclonal Antibody(IgG / IgM Positive Control)||ELISA|
Scientists are racing to learn the secrets of severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2), which is the cause of the pandemic disease COVID-19. The first step in viral entry is the binding of the viral trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2).
Immobilized Recombinant 2019-nCoV S-trimer Protein (C-6His)(Cat#PKSR030489) at 5.0ug/ml (100uL/well) can bind Anti-2019-nCoV S-hIgG1 Neutralizing Antibody (8A5), the EC50 is 2.9ng/ml.
Immobilized Recombinant 2019-nCoV S-trimer Protein (C-6His)(Cat#PKSR030489) at 5.0ug/ml (100uL/well) can bind Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5), the EC50 is 4.43ng/ml.